The selection of clinical trial sites could take into consideration different cultural and national attitudes toward research in pregnant women. Locations where research in pregnancy had not yet achieved public or regulatory acceptance could be avoided. Liability issues might also be reduced with stand-alone Phase I trials in pregnant women, since optimal sites would be obstetrical centers already insured for interventions in higher risk populations. Finally, slower enrollment into stand-alone Phase I trials involving pregnant women would not delay the analysis and reporting of data in non pregnant populations.